pharma

The biochemistry of the mystical – a psychedelics renaissance?

The biochemistry of the mystical – a psychedelics renaissance?

After a decades-long hiatus, research on psychedelics as a treatment for psychiatric diseases is experiencing a renaissance—and initial results look promising.

In the newest episode of the BioRevolution podcast, Andreas Horchler and Louise von Stechow discuss the history, the promise, and the risks of psychedelics as treatments for psychiatric diseases with neuroscientist, psychedelics expert, and executive coach Galyna Pidpruzhnykova

A question of trust - Why we need science

A question of trust - Why we need science

The value of facts and evidence-based science seems to be increasingly questioned by those in power and by those in control of assets. If those who make laws and regulate science don’t see evidence and consensus as reliable resources anymore, what will become of progress in biomedicine, which feeds innovation in biotech, pharma, and medicine?

More Boom or…Bust – What to expect from AI in biotech in 2025?

More Boom or…Bust – What to expect from AI in biotech in 2025?

In episode 31 of the BioRevolution podcast, Andreas Horchler and Louise von Stechow explore various use cases for AI in biotech—from discovery to clinical development, from chemistry to biology, and from data-centric to algorithm-centric AI strategies—trying to assess where the biggest payoff will be.